247 related articles for article (PubMed ID: 22114486)
1. Practical preparation procedures for docetaxel-loaded nanoparticles using polylactic acid-co-glycolic acid.
Keum CG; Noh YW; Baek JS; Lim JH; Hwang CJ; Na YG; Shin SC; Cho CW
Int J Nanomedicine; 2011; 6():2225-34. PubMed ID: 22114486
[TBL] [Abstract][Full Text] [Related]
2. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
3. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
Mu L; Feng SS
J Control Release; 2003 Jan; 86(1):33-48. PubMed ID: 12490371
[TBL] [Abstract][Full Text] [Related]
4. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity.
Yan F; Zhang C; Zheng Y; Mei L; Tang L; Song C; Sun H; Huang L
Nanomedicine; 2010 Feb; 6(1):170-8. PubMed ID: 19447200
[TBL] [Abstract][Full Text] [Related]
5. Polyelectrolyte coated polymeric nanoparticles for controlled release of docetaxel.
Agrawal R; Shanavas A; Yadav S; Aslam M; Bahadur D; Srivastava R
J Biomed Nanotechnol; 2012 Feb; 8(1):19-28. PubMed ID: 22515091
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
7. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment.
Feng SS; Zeng W; Teng Lim Y; Zhao L; Yin Win K; Oakley R; Hin Teoh S; Hang Lee RC; Pan S
Nanomedicine (Lond); 2007 Jun; 2(3):333-44. PubMed ID: 17716178
[TBL] [Abstract][Full Text] [Related]
8. Robust aptamer-polydopamine-functionalized M-PLGA-TPGS nanoparticles for targeted delivery of docetaxel and enhanced cervical cancer therapy.
Xu G; Yu X; Zhang J; Sheng Y; Liu G; Tao W; Mei L
Int J Nanomedicine; 2016; 11():2953-65. PubMed ID: 27382282
[TBL] [Abstract][Full Text] [Related]
9. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio.
Mu L; Feng SS
Pharm Res; 2003 Nov; 20(11):1864-72. PubMed ID: 14661934
[TBL] [Abstract][Full Text] [Related]
10. Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings.
Enlow EM; Luft JC; Napier ME; DeSimone JM
Nano Lett; 2011 Feb; 11(2):808-13. PubMed ID: 21265552
[TBL] [Abstract][Full Text] [Related]
11. Statistical design for formulation optimization of hydrocortisone butyrate-loaded PLGA nanoparticles.
Yang X; Patel S; Sheng Y; Pal D; Mitra AK
AAPS PharmSciTech; 2014 Jun; 15(3):569-87. PubMed ID: 24504495
[TBL] [Abstract][Full Text] [Related]
12. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA.
Perez C; Sanchez A; Putnam D; Ting D; Langer R; Alonso MJ
J Control Release; 2001 Jul; 75(1-2):211-24. PubMed ID: 11451511
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release.
Zhang Z; Feng SS
Biomaterials; 2006 Jan; 27(2):262-70. PubMed ID: 16024075
[TBL] [Abstract][Full Text] [Related]
14. PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release.
Halayqa M; Domańska U
Int J Mol Sci; 2014 Dec; 15(12):23909-23. PubMed ID: 25535080
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure.
McCarron PA; Donnelly RF; Marouf W
J Microencapsul; 2006 Aug; 23(5):480-98. PubMed ID: 16980271
[TBL] [Abstract][Full Text] [Related]
16. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
Kumar PS; Ramakrishna S; Saini TR; Diwan PV
Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
[TBL] [Abstract][Full Text] [Related]
17. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases.
Pirooznia N; Hasannia S; Lotfi AS; Ghanei M
J Nanobiotechnology; 2012 May; 10():20. PubMed ID: 22607686
[TBL] [Abstract][Full Text] [Related]
18. Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation.
Sahana B; Santra K; Basu S; Mukherjee B
Int J Nanomedicine; 2010 Sep; 5():621-30. PubMed ID: 20856837
[TBL] [Abstract][Full Text] [Related]
19. Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation.
Mehta AK; Yadav KS; Sawant KK
Curr Drug Deliv; 2007 Jul; 4(3):185-93. PubMed ID: 17627492
[TBL] [Abstract][Full Text] [Related]
20. Nanoformulation of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy.
Huang L; Chen H; Zheng Y; Song X; Liu R; Liu K; Zeng X; Mei L
Integr Biol (Camb); 2011 Oct; 3(10):993-1002. PubMed ID: 21938302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
